Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 540-546

  Lin, Xiaojuan ^a   Chen, Xiancheng ^a   Wei, Yuquan ^b   Zhao, Jumei ^b   Fan, Linyu ^b   Wen, Yanjun ^b   Wu, Hongbo ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cationic liposome; Lymphocyte accumulation; Ovarian cancer; Vesicular stomatitis virus matrix protein (VSVMP)

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; LIPOSOME; MATRIX PROTEIN; PLASMID DNA; PLASMID VECTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS MATRIX PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; RECOMBINANT PLASMID; STATISTICAL SIGNIFICANCE; TUMOR RESISTANCE; VESICULAR STOMATITIS VIRUS;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DNA, COMPLEMENTARY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RANDOM ALLOCATION; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846925929     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.022     Document Type: Article

References (28)

1. Koyama A.H. Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res. 37 (1995) 285-290
2. Balachandran S., and Barber G.N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50 (2000) 135-138
3. Balachandran S., and Barber G.N. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5 (2004) 51-65
4. Balachandran S., Porosnicu M., and Barber G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75 (2001) 3474-3479
5. Fernandez M., Porosnicu M., Markovic D., and Barber G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76 (2002) 895-904
6. Stojdl D.F., Lichty B., Knowles S., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6 (2000) 821-825
7. Li Q., Wei Y.Q., Wen Y.J., et al. Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int. J. Cancer 112 (2004) 143-149
8. Black B.L., and Lyles D.S. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J. Virol. 66 (1992) 4058-4064
9. Black B.L., Rhodes R.B., McKenzie M., and Lyles D.S. The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J. Virol. 67 (1993) 4814-4821
10. Paik S.Y., Banerjea A.C., Harmison G.G., Chen C.J., and Schubert M. Inducible and conditional inhibition of human immunodeficiency virus proviral expression by vesicular stomatitis virus matrix protein. J. Virol. 69 (1995) 3529-3537
11. Blondel D., Harmison G.G., and Schubert M. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J. Virol. 64 (1990) 1716-1725
12. Lyles D.S., and McKenzie M.O. Activity of vesicular stomatitis virus M protein mutants in cell rounding is correlated with the ability to inhibit host gene expression and is not correlated with virus assembly function. Virology 299 (1997) 77-89
13. Kopecky S.A., Willingham M.C., and Lyles D.S. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J. Virol. 75 (2001) 12169-12181
14. Kopecky S.A., and Lyles D.S. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J. Virol. 77 (2003) 5524-5528
15. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J. Clin. 54 (2004) 9-29
16. Ozols R.F. Progress in ovarian cancer: an overview and perspective. EJC Suppl. 2 (2003) 43-55
17. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
18. Xu G.X., Zhong Y., Munir S., Yang B.B., Tsang B.K., and Peng C. Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J. Clin. Endocrinol. Metab. 89 (2004) 5523-5534
19. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7 (2001) 781-787
20. Bell J.C., Lichty B., and Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 4 (2003) 7-11
21. Letchworth G.J., Rodriguez L.L., and Del C.B.J. Vesicular stomatitis. Vet. J. 157 (1999) 239-260
22. Desforges M., Despars G., Berard S., et al. Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neutral cells by vesicular stomatitis virus. Virology 295 (2002) 63-73
23. Sellers W.R., and Fisher D.E. Apoptosis and cancer drug targeting. J. Clin. Invest. 104 (1999) 1655-1661
24. Pross H.F., and Lotzova E. Role of natural killer cells in cancer. Nat. Immun. 12 (1993) 279-292
25. Whiteside T.L., and Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7 (1995) 704-710
26. Habu S., Fukui H., Shimamura K., et al. In vivo effects of anti-asialo GM1 I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127 (1981) 34-38
27. Yuan F., Lwunig M., Huang S.K., Berk D.A., Papahadjopoulos D., and Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54 (1994) 3352-3356
28. Harrington K.J., Mohammadtaghi S., Uster P.S., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled PEGylated liposomes. Clin. Cancer Res. 7 (2001) 243-254